<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131292">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02131077</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-ASC-TI-201</org_study_id>
    <nct_id>NCT02131077</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Allogeneic Adipose-derived Stem Cells for Treatment of Lateral Epicondylitis</brief_title>
  <official_title>A Multi-center, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase I/II Clinical Study to Evaluate Safety and Efficacy of Allogeneic Adipose-derived Stem Cells for the Treatment of Lateral Epicondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety (MFDS)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of allogeneic
      adipose-derived stem cells (ALLO-ASC) in patients with lateral epicondylitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinically measured abnormality of laboratory tests and adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement of VAS pain score at 12 weeks compared to baseline per each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS pain score</measure>
    <time_frame>week 2, week 6 and week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in the VAS pain score during activity per each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pain score</measure>
    <time_frame>week 2, week 6 and week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement rate of VAS pain score at rest per each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Mayo Clinic Performance Index</measure>
    <time_frame>week 2, week 6 and week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Modified Mayo Clinic Performance Index per each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasonic photography</measure>
    <time_frame>week 6 and week 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in analysis of lesion size per each group</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Tennis Elbow</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-ASC-TI</intervention_name>
    <arm_group_label>treatment</arm_group_label>
    <other_name>Allogenic adipose-derived stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>treatment</arm_group_label>
    <other_name>0.9% Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Older than 19 years.

          2. Patients who are diagnosed as lateral epicondylitis (Painâ‰¥4 of VAS during activity).

          3. Patients who has sustained pain more than 6 months

          4. Patients who lasting for pain in spite of conservative therapy

          5. Patients who have one lesion under ultrasonic photography

          6. Negative for urine beta-HCG for women of childbearing age

          7. Patient who is able to give written informed consent prior to study start and to
             comply with the study requirements

        Exclusion Criteria:

          1. Patients who has been experienced steroid and prolotherapy or other treatment within
             3 months at screening time

          2. Patients who have lesion size of width and length more than 1 cm using ultrasonic
             photography test

          3. Patients who were accompanied by the disease as follows: A. Arthritis of related
             joint to the target lesiom (ex, cubital osteo- arthritis), B.Synovitis of related
             joint to the target lesion, C.Entrapment of related nerve to the target lesion(ex,
             radial tunnel syndrome), D.Generalized pain syndrome, E.Radiculopathy related to the
             target lesion(ex, cervical spodylosis ,cervical radicular syndrome), F.Rheumatoid
             arthritis, G.Previous fracture of arm causing limitations in arm function, H.Impaired
             sensibility, I.Paralysis

          4. Patients who are pregnant or breast-feeding

          5. Patients who have allergic or hypersensitive reaction to bovine-derived proteins or
             fibrin glue

          6. Patients who have history of fracture and dislocation at Ipsilateral upper extremity
             within 2 years recently

          7. Patients who have operation history in tendon, ligament and bone at Ipsilateral upper
             extremity within 2 years recently

          8. Patients who are unwilling to use an &quot;effective&quot; method of contraception during the
             study

          9. Patients who have a clinically relevant history of abuse of alcohol or drugs

         10. Patients who are considered not suitable for the study by investigator

         11. Patients who have experienced treatment with stem cell before this study

         12. Patients who currently enrolled in another investigational drug study within 30 days
             of screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S G Chung, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>S G Chung, MD., PhD</last_name>
    <phone>82-2-2072-3954</phone>
    <email>suncg@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S G Chung, M.D., Ph. D</last_name>
      <phone>82-2-2072-3954</phone>
      <email>chung60611@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J H Park, M.D.</last_name>
      <phone>82-2-2019-3491</phone>
      <email>RMPJH@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanoori hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C W Lee, M.D., Ph.D.</last_name>
      <phone>82-2-1688-9797(direct 1812)</phone>
      <email>hipson4206@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K H Choi, M.D., Ph.D.</last_name>
      <phone>Tel.82-2-3010-3800</phone>
      <email>khchoi@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hosptal</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D K Kim, M.D., Ph. D</last_name>
      <phone>82-2-6299-1866</phone>
      <email>Donkim21@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lateral Epicondylitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tennis Elbow</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
